Is IMGN a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,708 people get IMGN articles and Market Currents by email alert.

Get email alerts on IMGN »

HEADLINES:

ImmunoGen's Management Presents at Credit Suisse Antibody Day Conference (Transcript)
Sat, May 11 • 1 Comment
ImmunoGen's Symbiotic Relationships Thru TAP Will Beef Up Its Stock Price
Somsanith Donesing • Thu, May 9 • 4 Comments
ImmunoGen, Inc. Announces Webcast of Presentation at Upcoming Investor Conference

Business Wire (May 3, 2013)
ImmunoGen's CEO Discusses F3Q 2013 Results - Earnings Call Transcript
Fri, Apr 26
ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update

Business Wire (Apr 26, 2013)
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2013 Financial Results

Business Wire (Apr 18, 2013)
Cramer's Lightning Round- Kicking Myself Over Toll Brothers (4/16/13)
SA Editor Miriam Metzinger • Wed, Apr 17
ImmunoGen Offers New Hope For Treatment Of Subtypes Of Squamous Cell Carcinomas And Other Cancers
Prohost Biotech • Sun, Apr 14 • 6 Comments
Playing To The Strengths Of Biotech
Richard Cox • Sat, Apr 13 • 5 Comments
ImmunoGen's CEO Hosts Analyst and Investor Day (Transcript)
Sat, Apr 13
Webcast of the ImmunoGen, Inc. Analyst and Investor Community Meeting on April 12, 2013

Business Wire (Apr 11, 2013)
ImmunoGen, Inc. Announces Preclinical Findings with its IMGN289 Product Candidate for the Treatment of EGFR-Overexpressing Cancers

Business Wire (Apr 10, 2013)
Cramer's Mad Money - 13 Things To Watch In The Week Ahead (4/5/13)
SA Editor Miriam Metzinger • Sun, Apr 7 • 3 Comments
Cramer's Mad Money - Economists Don't Know Jack About Stocks (4/4/13)
SA Editor Miriam Metzinger • Fri, Apr 5 • 2 Comments
Cramer's Mad Money - Top 10 S&P 500 Stocks For The First Quarter (4/1/13)
SA Editor Miriam Metzinger • Tue, Apr 2 • 5 Comments
ImmunoGen, Inc. Announces Webcast of its Analyst and Investor Community Meeting on April 12, 2013

Business Wire (Mar 12, 2013)
After FDA Approval, A New And Bigger Catalyst Looms Closer For Immunogen
Brian L. Wilson • Mon, Mar 11 • 13 Comments
The Future Of Breast Cancer Treatment And What It Means For Roche And ImmunoGen
Bio Matt • Thu, Feb 28
Cramer's Mad Money - The Single Best Earnings Call Of 2013 So Far (2/26/13)
SA Editor Miriam Metzinger • Wed, Feb 27 • 3 Comments
ImmunoGen's CEO Presents at Citi 2013 Global Healthcare Conference (Transcript)
Mon, Feb 25

To learn more about Seeking Alpha Pro, click here.

ImmunoGen's Symbiotic Relationships Thru TAP Will Beef Up Its Stock Price
Somsanith Donesing • Thu, May 9 • 4 Comments
ImmunoGen Offers New Hope For Treatment Of Subtypes Of Squamous Cell Carcinomas And Other Cancers
Prohost Biotech • Sun, Apr 14 • 6 Comments
After FDA Approval, A New And Bigger Catalyst Looms Closer For Immunogen
Brian L. Wilson • Mon, Mar 11 • 13 Comments
The Future Of Breast Cancer Treatment And What It Means For Roche And ImmunoGen
Bio Matt • Thu, Feb 28
T-DM1 Approval Benefits Technology More Than It Does ImmunoGen
EP Vantage • Mon, Feb 25
ImmunoGen, Surprisingly Quiet Ahead Of FDA Decision
Brian L. Wilson • Thu, Feb 14 • 9 Comments
Why Analysts Are Dead Wrong On Immunogen
John Li • Wed, Jan 30 • 11 Comments
ImmunoGen's Press Release Is More Than Mere News
Prohost Biotech • Tue, Dec 4, 2012 • 3 Comments
Why Immunogen Is Undervalued
John Li • Mon, Nov 12, 2012 • 7 Comments
Immunogen Revenue Can Be Much Higher Than Analyst Predictions
John Li • Thu, Nov 1, 2012 • 7 Comments
Is ImmunoGen More Than T-DM1?
Stephen Simpson • Tue, Oct 2, 2012 • 7 Comments
ImmunoGen: 2 Pieces Of Good News In 1 Announcement
Prohost Biotech • Mon, Aug 27, 2012 • 6 Comments
ImmunoGen Has Good News To Share
Prohost Biotech • Tue, Jun 5, 2012 • 3 Comments
Why It's Time to Sell ImmunoGen
Ohad Hammer • Mon, Jul 25, 2011 • 11 Comments
Cancer Drug Developers Considering ImmunoGen's Tap Technology
Prohost Biotech • Wed, Jun 15, 2011 • 6 Comments
ImmunoGen and the Second Lethal Virus
Prohost Biotech • Fri, Oct 29, 2010 • 2 Comments
Immunogen's T-DM1 Gets Presidential Treatment
Ohad Hammer • Sun, Oct 3, 2010
Why I Bought ImmunoGen After the Plunge
Marco G. • Sun, Aug 29, 2010 • 13 Comments
The Rush to Buy ImmunoGen
Prohost Biotech • Fri, Mar 19, 2010
Time to Buy ImmunoGen
Beta Delta • Thu, Dec 4, 2008

Cramer's Lightning Round- Kicking Myself Over Toll Brothers (4/16/13)
SA Editor Miriam Metzinger • Wed, Apr 17
Playing To The Strengths Of Biotech
Richard Cox • Sat, Apr 13 • 5 Comments
Cramer's Mad Money - 13 Things To Watch In The Week Ahead (4/5/13)
SA Editor Miriam Metzinger • Sun, Apr 7 • 3 Comments
Cramer's Mad Money - Economists Don't Know Jack About Stocks (4/4/13)
SA Editor Miriam Metzinger • Fri, Apr 5 • 2 Comments
Cramer's Mad Money - Top 10 S&P 500 Stocks For The First Quarter (4/1/13)
SA Editor Miriam Metzinger • Tue, Apr 2 • 5 Comments
Cramer's Mad Money - The Single Best Earnings Call Of 2013 So Far (2/26/13)
SA Editor Miriam Metzinger • Wed, Feb 27 • 3 Comments
5 Rules For Speculating In Biotech
Marc Lichtenfeld • Wed, Jan 30 • 2 Comments
4 Promising Growth Stories In Therapeutics
Cris Frangold • Fri, Jan 18 • 4 Comments
Upcoming FDA Approval Decision Dates For Q1 2013
David Zanoni • Sun, Jan 13 • 13 Comments
Cramer's Mad Money - Tupperware Is Fit For A Queen (12/10/12)
SA Editor Miriam Metzinger • Tue, Dec 11, 2012
Show Me The Money: ADC Revenue Payloads Miss The Mark
Michael Webb • Mon, Nov 26, 2012 • 20 Comments
3 Acquisitions In Biotechnology That Could Occur In The Next Year
Brian Nichols • Sun, Nov 11, 2012 • 35 Comments
Investment Opportunities Surface With 3 Vaccine Players
Cris Frangold • Tue, Nov 6, 2012 • 4 Comments
Investing In Novel Drug Delivery Ideas
Peter Geschek • Wed, Oct 3, 2012 • 3 Comments
Seattle Genetics: Positive Read-Through From Roche's Investor Day
Ohad Hammer • Mon, Sep 10, 2012 • 9 Comments
Roche Hosts An Encouraging Investor Day
Stephen Simpson • Thu, Sep 6, 2012 • 2 Comments
Upcoming Catalysts For Exelixis And Immunogen
Ohad Hammer • Mon, Aug 27, 2012 • 9 Comments
Galena Showing Similarities To ImmunoGen And Looks To Follow Its Path
Brian Nichols • Wed, Aug 15, 2012 • 8 Comments
Why A Sell-Off Among The Best Oncology Biotech Firms?
Prohost Biotech • Wed, Aug 15, 2012 • 12 Comments
Disruptive Biotechnologies Stir Up Profits: Ray Blanco
Life Sciences Report • Mon, Aug 6, 2012 • 4 Comments

ImmunoGen's Management Presents at Credit Suisse Antibody Day Conference (Transcript)
Sat, May 11 • 1 Comment
ImmunoGen's CEO Discusses F3Q 2013 Results - Earnings Call Transcript
Fri, Apr 26
ImmunoGen's CEO Hosts Analyst and Investor Day (Transcript)
Sat, Apr 13
ImmunoGen's CEO Presents at Citi 2013 Global Healthcare Conference (Transcript)
Mon, Feb 25
ImmunoGen's CEO Discusses F2Q 2013 Results - Earnings Call Transcript
Fri, Jan 25
ImmunoGen's CEO Presents at the JP Morgan Healthcare Conference (Transcript)
Mon, Jan 7 • 1 Comment
ImmunoGen's Management Presents at Lazard Capital Markets 9th Annual Healthcare Conference (Transcript)
Wed, Nov 14, 2012 • 1 Comment
ImmunoGen's CEO Discusses F1Q13 Results - Earnings Call Transcript
Fri, Oct 26, 2012 • 2 Comments
ImmunoGen's CEO Presents at UBS 2012 Global Life Sciences Conference (Transcript)
Thu, Sep 20, 2012
ImmunoGen's CEO Presents at Morgan Stanley Global Healthcare Conference - Transcript
Wed, Sep 12, 2012
ImmunoGen's CEO Discusses F4Q12 Results - Earnings Call Transcript
Fri, Aug 3, 2012
ImmunoGen CEO Discusses F1Q11 Results - Earnings Call Transcript
Fri, Oct 29, 2010
ImmunoGen, Inc. F4Q10 (Qtr End 06/30/10) Earnings Call Transcript
Wed, Aug 4, 2010
ImmunoGen, Inc. F3Q10 (Qtr End 03/31/10) Earnings Call Transcript
Mon, May 3, 2010
ImmunoGen, Inc. F2Q10 (Qtr End 12/31/09) Earnings Call Transcript
Fri, Jan 29, 2010
ImmunoGen, Inc. F3Q09 (Quarter End 03/31/09) Earnings Call Transcript
Thu, Apr 30, 2009
ImmunoGen, Inc. F2Q09 (Qtr End 12/31/08) Earnings Call Transcript
Tue, Feb 17, 2009
ImmunoGen, Inc. F1Q09, (Qtr End 9/30/08) Earnings Call Transcript
Mon, Oct 27, 2008
ImmunoGen, Inc. F4Q08 (Qtr End 06/30/08) Earnings Call Transcript
Mon, Sep 8, 2008
ImmunoGen Business Update Call Transcript
Tue, Dec 11, 2007

ImmunoGen, Inc. Announces Webcast of Presentation at Upcoming Investor Conference

Business Wire (May 3, 2013)
ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update

Business Wire (Apr 26, 2013)
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2013 Financial Results

Business Wire (Apr 18, 2013)
Lightning Round: Dollar Tree, Toll Brothers & More

at CNBC.com (Apr 16, 2013)
Webcast of the ImmunoGen, Inc. Analyst and Investor Community Meeting on April 12, 2013

Business Wire (Apr 11, 2013)
ImmunoGen, Inc. Announces Preclinical Findings with its IMGN289 Product Candidate for the Treatment of EGFR-Overexpressing Cancers

Business Wire (Apr 10, 2013)
Cramer's Stock Market Strategies for the Week Ahead

at CNBC.com (Apr 5, 2013)
Cramer: Investing in Future of Cancer Drugs

at CNBC.com (Apr 4, 2013)
ImmunoGen, Inc. Announces Webcast of its Analyst and Investor Community Meeting on April 12, 2013

Business Wire (Mar 12, 2013)
ImmunoGen, Inc. Announces FDA Approval of Kadcyla (Ado-Trastuzumab Emtansine; Also Known as T-DM1)

Business Wire (Feb 22, 2013)
ImmunoGen, Inc. Attains Patient Enrollment Milestone in IMGN901 NORTH Trial

Business Wire (Feb 12, 2013)
ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences

Business Wire (Feb 5, 2013)
ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update

Business Wire (Jan 25, 2013)
ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2013 Financial Results

Business Wire (Jan 18, 2013)
ImmunoGen, Inc. Announces Webcast of Presentation at the 31st Annual J.P. Morgan Healthcare Conference

Business Wire (Jan 2, 2013)
Amgen Takes Third License for Rights to Use ImmunoGen’s TAP Technology

Business Wire (Dec 19, 2012)
ImmunoGen, Inc. Announces IMGN901 Clinical Data Presented at ASH

Business Wire (Dec 10, 2012)
ImmunoGen, Inc. Announces Webcast of Presentation at the Oppenheimer 23rd Annual Healthcare Conference

Business Wire (Dec 6, 2012)
ImmunoGen, Inc. Announces Clinical Data Presentations at the 54th ASH Annual Meeting and Exposition

Business Wire (Dec 3, 2012)
ImmunoGen, Inc. Appoints Dr. Charles Morris as Chief Development Officer

Business Wire (Nov 26, 2012)

IMGN vs. ETF Alternatives

Company Description

We develop novel, targeted therapeutics for the treatment of cancer using our expertise in cancer biology, monoclonal antibodies, highly potent cytotoxic, or cell-killing, agents, and the design of linkers that enable these agents to be stably attached to the antibodies while in the blood stream... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, April 26, 6:31 AM Immunogen (IMGN): FQ3 EPS of -$0.02 beats by $0.12. Revenue of $25M beats by $13.06M. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
Friday, April 26, 12:05 AM Notable earnings before Friday’s open: ABBV, AEP, AON, ARLP, B, BKW, BPO, COV, CVX, DHI, DLR, DTE, FLIR, GDI, GNC, GT, HMSY, IMGN, ITRI, LAZ, LYB, MPW, NOV, SPG, TRP, TYC, VFC, VTR, WETF, WY Comment! [Earnings]
Thursday, April 25, 5:30 PM Notable earnings before Friday’s open: ABBV, AEP, AON, ARLP, B, BKW, BPO, COV, CVX, DHI, DLR, DTE, FLIR, GDI, GNC, GT, HMSY, IMGN, ITRI, LAZ, LYB, MPW, NOV, SPG, TRP, TYC, VFC, VTR, WETF, WY Comment! [Earnings]
Wednesday, April 10, 8:36 AM Immunogen (IMGN) gets a lift early after saying preclinical studies show its antibody-drug conjugate is "highly active" against some over expressing cancer cells. IMGN says the skin cancer compound is "on track to become [its] fourth wholly owned clinical-stage" drug with trials to begin later this year. Shares +1.43% premarket. 2 Comments [Healthcare, On the Move]
Thursday, April 4, 2:37 PM ImmunoGen (IMGN +1.8%) says it's amended its multi-target agreement with Novartis (NVS -0.6%), which was originally entered into in October, 2010. As a result, IMGN is eligible to receive a $1M upfront fee and the opportunity to receive milestone payments potentially totaling approximately $200M or $238M, depending on the composition of any resultant products. 1 Comment [Healthcare, On the Move]
Friday, February 22, 10:27 AM More on ImmunoGen (IMGN): The stock's moving about quite a bit, but currently +3.8% following FDA approval of Kadcyla. The drug is being approved with a Boxed Warning alerting users and prescribers of heart and liver toxicity as well as severe life-threatening birth defects. 3 Comments [Healthcare, On the Move]
Friday, February 22, 9:26 AM The FDA has approved ImmunoGen's (IMGN) breast cancer drug TDM1, now called Kadcyla. The approval triggers a $10.5M milestone payment to ImmunoGen, with royalties from sales to follow. Shares are halted. (PR) Comment! [Healthcare, Breaking News]
Tuesday, February 12, 2:34 PM ImmunoGen (IMGN -1.2%) say's it's completed patient enrollment in the first stage of its NORTH two-stage Phase II trial assessing IMGN901, a first-line treatment candidate for small-cell lung cancer. Attaining this milestone enables the findings from the planned interim analysis at 6 months to be available in H213. Comment! [Healthcare]
Monday, January 28, 2:52 PM ImmunoGen (IMGN -2.8%) slides after Oppenheimer cut the shares to Perform earlier today, saying that the success of its current breast cancer drug T-DM1 is now fully priced into the stock. As with the launch any drug launch, initial Street expectations are adjusted, and a post-launch pullback into low teens may be seen over the near term. Comment! [Healthcare, On the Move]
Friday, January 25, 1:56 PM Shares of Immunogen (IMGN -2.4%) slip today after its FQ2 loss comes in wider than the analyst consensus. Revenue fell 65% Y/Y on an absence of milestone payments, while higher R&D costs hurt its bottom line. The company attributes the higher expenses to greater investment in advancing its wholly owned product candidates, increased clinical trial costs, and increased personnel expenses. The biotech firm maintained its FY13 guidance, calling for a net loss of $70M to $74M. Comment! [Healthcare, Earnings, On the Move]
Friday, January 25, 6:37 AM Immunogen (IMGN): FQ2 EPS of -$0.29 misses by $0.04. Revenue of $2.6M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, January 25, 12:05 AM Notable earnings before Friday’s open: AEP, COV, HAL, HON, IMGN, KMB, OSK, PG, WY Comment! [Earnings]
Thursday, January 24, 5:30 PM Notable earnings before Friday’s open: AEP, COV, HAL, HON, IMGN, KMB, OSK, PG, WY Comment! [Earnings]
Monday, January 14, 2:32 PM Investors interested in the prospects of young biotech companies might want to take a look at this Seeking Alpha article. It's a list of the upcoming FDA approval decision dates for Q1 2013, and with many of these developing firms having a good portion of their businesses riding on FDA approval decisions for their newly developed drugs, the stocks are likely to be sensitive to any positive or negative news over the near term. Comment! [Healthcare, Quick Ideas]
Wednesday, December 19, 2012, 11:39 AM ImmunoGen (IMGN -0.5%) says that Amgen (AMGN -0.2%) has licensed the exclusive right to use the company's maytansinoid TAP technology to develop anticancer therapeutics to a third target, which is undisclosed. For each license, IMGN receives a $1M upfront payment and is entitled to receive milestone payments potentially totaling $34M plus royalties on the sales of any resulting products. AMGN is responsible for the development, manufacturing and marketing of any products resulting from the license. Comment! [Healthcare]
Monday, December 10, 2012, 5:58 PM ImmunoGen (IMGN) presents new clinical data on it's targeted anticancer compound, IMGN901, saying that - in cases where it was evaluated as single-agent therapy – the evidence supports further development of the drug as a treatment for CD56-expressing cancers. Shares +0.3% AH. Comment! [Healthcare]

tomlewis727
$IMGN got the FDA approval today
Feb 22, 10:57 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

johnjail
Finally opened a position in IMGN !! very goooood! next step open a position in INCY
8/16/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
6 Analyst Backed Small Cap Biotech Stocks With Plenty Of Cash Cash http://bit.ly/Nr2Ftd $ACOR $CADX $IMGN $QLTI $VPHM $VVUS @ZetaKap
8/3/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
7 Fast Growth Healthcare Stocks With Generous Reserves http://bit.ly/QdI4wS $SRDX $CPIX $IMGN $MELA $QLTI $VVUS $CORT @ZetaKap
7/31/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/LLbXG0 Premarket gainer $INFY (11%), $SVU (35%), $IMGN (7%)
7/12/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
5 High-Growth Healthcare Small Caps Armed With Cash http://bit.ly/KOekl0 $CPIX $SRDX $HTWR $IMGN $LMNX @ZetaKap
7/2/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/I5Ernm Earning to focus before market opens: COV, F, HMC, IMAX, IMGN, IP, MRK, NVO, PG, SNY, GT, WY, VFC
4/26/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

RobertoD
It is odd that the IMGN stock price is not going up when there is a fast track FDA approval coming down probably as soon as May.
3/11/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Stockwatcher91
IMGN is ready to pop to 14.50
3/8/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Nigam Arora
IMMUNOGEN (IMGN): WHAT TO DO NOW Check out details..... http://bit.ly/e4IPcU/
9/26/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

IMGN ImmunoGen, Inc.

IMGN

ImmunoGen, Inc.